Noninferiority margin for clinical trials of antibacterial drugs for nosocomial pneumonia

Drug Information Journal

Volumn 44, Issue 2, 2010, Pages 165-176

  Sorbello, Alfred ^a   Komo, Scott ^a   Valappil, Thamban ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

All cause mortality; Noninferiority margin; Nosocomial pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HOSPITAL INFECTION; HUMAN; MATHEMATICAL ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 77954891091     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400208     Document Type: Article

References (36)

1. Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep. 2007:122:160.
2. Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest. 1988;93(2):318-324. (Pubitemid 18053068)
3. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med. 2007;35(2):379-385.
4. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412-420. (Pubitemid 28110020)
5. Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 1990;142:523-528. (Pubitemid 20292709)
6. Alvarez-Lerma F, ICU-Acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22:387-394.
7. Leroy O, Meybeck A, d'Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med. 2003;29:2170-2173.
8. Rello J, Vidaur L, Sandiumenge A, et al. Deescalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183-2190.
9. Teixeira PJZ, Seligman R, Hertz FT, Cruz DB, Fachel JMG. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect. 2007;65:361-367. (Pubitemid 46485289)
10. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment of ventilator-associated pneumonia. Chest. 2002;122:262-268. (Pubitemid 34754172)
11. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection scores as an early clinical predictor of outcome. Crit Care Med. 2003;31:676-682. (Pubitemid 36379567)
12. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;111:676-685.
13. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;27:158-164.
14. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
15. US Food and Drug Administration. Points to consider: clinical development and labeling of antiinfective drug products. 1992. Retrieved on November 4, 2009, from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070975.pdf.
16. US Food and Drug Administration. Guidance for industry - nosocomial pneumonia - developing antimicrobial drugs for treatment. 1998. Retrieved on January 6, 2010, from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071170.pdf.
17. International Conference on Harmonization. ICH E10. Choice of control group and related issues in clinical trials. Retrieved on October 26, 2009, from: http://www.fda.gov/RegulatoryInformation/Guidances/ucm125802.htm.
18. US Food and Drug Administration. Guidance for industry - antimicrobial drug products: use of noninferiority studies to support approval (draft guidance). 2007. Retrieved on October 26, 2009, from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070951.pdf.
19. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
20. Hung HMJ, Wang SJ, O'Neill R. A regulatory perspective on choice of margin and statistical inference in non-inferiority trials. Biometrical J. 2005;47(1):28-36. (Pubitemid 40390436)
21. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47(11):3442-3447.
22. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin. 2008;24(7):2113-2126.
23. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089-1096. (Pubitemid 351482655)
24. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 2003;25:485-506. (Pubitemid 36286915)
25. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008;134:1200-1207.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
27. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-69. (Pubitemid 46780603)
28. Stevens RM, Teres D, Skillman J, Feingold DS. Pneumonia in an intensive care unit: a 30 month experience. Arch Intern Med. 1974;134:106-111.
29. Smith IM, Champion MC, Hazard EC, Lowry L, Leaverton PE. Single and combined antibiotics in the treatment of Pseudomonas aeruginosa infections. In: Progress in Antimicrobial and Anticancer Chemotherapy: Proceedings of the 6th International Congress of Chemotherapy. Vol. 1. Baltimore, MD: University Park Press, 1970:718-724.
30. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study, Clin Infect Dis. 2001;32:402-412.
31. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, and the Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980-992.
32. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother. 1994;38:547-557.
33. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective, randomized, multicenter trial. Intensive Care Med. 2001;27:493-502. (Pubitemid 32250078)
34. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C, and the VAP Study Group. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized, controlled trial. Clin Infect Dis. 1998;26:346-354.
35. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med. 2006;100:1554-1565. (Pubitemid 44089364)
36. Schmitt DV, Leitner E, Weite T, Lode H. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind, prospective, multicenter study. Infection. 2006;34:127-134. (Pubitemid 43979660)